GO:0005153 interleukin-8 receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005153 (interleukin-8 receptor binding) is a molecular_function term describing the binding of a ligand to an interleukin-8 receptor.
• The primary ligands are the chemokines CXCL8 (IL-8) and related ELR+ CXC chemokines, which bind CXCR1 and CXCR2.
• IL-8 binding to CXCR1/CXCR2 triggers G-protein-coupled signaling that drives neutrophil chemotaxis and activation.
• Monomer-dimer equilibrium of IL-8 regulates receptor binding: dimer dissociation is essential for CXCR1 binding, and the dimer has altered receptor activity.
• Binding thermodynamics and receptor N-terminal domain interactions have been characterized for CXCR1.
• Dysregulated IL-8 receptor binding contributes to cancer, chronic inflammation, and senescence.
Description
Interleukin-8 (IL-8), now designated CXCL8, is a prototypical CXC chemokine that orchestrates neutrophil recruitment and activation during inflammation. The molecular function GO:0005153, interleukin-8 receptor binding, captures the specific interaction between IL-8 (or related ligands) and its cognate receptors, CXCR1 and CXCR2. This binding event is the first committed step in a signaling cascade that shapes innate immune responses, angiogenesis, and tissue repair. Because IL-8 receptor binding is implicated in diverse pathologies, from psoriasis and rheumatoid arthritis to tumor progression, it remains a focal point for drug discovery and functional genomics. Understanding the structural and thermodynamic basis of this interaction is essential for designing antagonists and for interpreting CRISPR screens that target chemokine signaling. This article integrates authoritative GO annotation with verified PubMed literature to provide a research-grade overview of GO:0005153, its mechanisms, key genes, and experimental models.
interleukin-8 receptor binding At A Glance
| GO ID | GO:0005153 |
|---|---|
| GO term | interleukin-8 receptor binding |
| Ontology | molecular_function |
| Synonym | IL-8, interleukin-8 receptor ligand |
| Major function | Binding to CXCR1 or CXCR2 to initiate chemokine signaling |
| Primary ligands | CXCL8 (IL-8) and related ELR+ CXC chemokines |
| Receptors | CXCR1 (IL8RA) and CXCR2 (IL8RB) |
| Modulators | Heparin, alpha2-macroglobulin, ligand dimerization |
| Related processes | Neutrophil chemotaxis, inflammation, angiogenesis, senescence |
What Is GO:0005153?
According to the Gene Ontology, GO:0005153 (interleukin-8 receptor binding) is a molecular function defined as binding to an interleukin-8 receptor. In practice, this term annotates gene products that physically interact with either CXCR1 or CXCR2, the two high-affinity receptors for IL-8/CXCL8. The binding is non-covalent and reversible, and it can be modulated by ligand oligomerization, glycosaminoglycans, and receptor N-terminal domains.
Why Is interleukin-8 receptor binding Important in Cell Biology?
GO:0005153 is important because it defines the molecular recognition event that initiates IL-8 signaling, a central axis in acute and chronic inflammation. This binding event controls neutrophil recruitment, a first-line defense against infection, and its dysregulation is linked to inflammatory diseases and cancer progression. Moreover, the interaction is a validated drug target: blocking IL-8 binding to CXCR1/CXCR2 with small molecules or antibodies can attenuate pathological inflammation. In cancer biology, IL-8 receptor binding reinforces senescence and promotes tumorigenesis through CXCR2 signaling. Thus, understanding this term at molecular, cellular, and organismal levels is critical for both basic immunology and translational medicine.
• Defines the initial step of IL-8 signaling, a key driver of neutrophil chemotaxis.
• CXCR1/CXCR2 binding by IL-8 is implicated in inflammatory skin diseases such as psoriasis.
• IL-8 receptor binding via CXCR2 reinforces cellular senescence, a tumor-suppressive mechanism.
• Heparin and alpha2-macroglobulin modulate IL-8 binding, affecting its bioavailability.
• Ligand dimerization regulates receptor binding activity, adding a layer of control.
• Thermodynamic characterization of IL-8 binding to CXCR1 N-terminal domain informs drug design.
• The interaction is conserved in evolution, as shown by CXCR2 characterization in fish.
• CRISPR screens targeting IL-8 receptors can uncover new roles in immunity and cancer.
• IL-8 receptor binding is a potential therapeutic target for inflammatory diseases.
• Understanding binding specificity helps distinguish CXCR1 versus CXCR2 functions.
Molecular Mechanism of interleukin-8 receptor binding
Ligand Recognition and Receptor N-terminal Domain Engagement
In simple terms: IL-8 grabs onto the outer tail of its receptor to start a signal.
IL-8 (CXCL8) binds to the N-terminal domain of CXCR1 and CXCR2, a region rich in acidic residues that provides the primary docking site. Thermodynamic studies using isothermal titration calorimetry have shown that the IL-8 monomer binds the CXCR1 N-terminal domain with nanomolar affinity, driven by favorable enthalpy and entropy changes. This initial recognition is essential for subsequent receptor activation and G-protein coupling.
Role of Ligand Dimerization and Monomer-Dimer Equilibrium
In simple terms: IL-8 can pair up, but it must split apart to bind the receptor tightly.
IL-8 exists in a monomer-dimer equilibrium, and dimer dissociation is essential for high-affinity binding to CXCR1. A disulfide-trapped dimer of IL-8 was used to probe receptor binding activity, revealing that the dimer has altered binding properties compared to the monomer. These findings indicate that the oligomeric state of IL-8 is a critical determinant of GO:0005153 activity.
Modulation by Glycosaminoglycans and Plasma Proteins
In simple terms: Other molecules like heparin can stick to IL-8 and change how well it binds its receptor.
Heparin and alpha2-macroglobulin regulate IL-8 binding and function. Heparin can sequester IL-8, while alpha2-macroglobulin can covalently bind and inactivate it, thereby modulating the effective concentration of ligand available for receptor binding. These interactions highlight that GO:0005153 is not a simple binary event but is influenced by the extracellular matrix and plasma environment.
Receptor Activation and Downstream Signaling
In simple terms: Once IL-8 binds, the receptor changes shape and triggers signals inside the cell.
Binding of IL-8 to CXCR1/CXCR2 induces conformational changes that activate heterotrimeric G-proteins, leading to downstream signaling cascades including calcium flux, PI3K/AKT, and MAPK pathways. This signaling drives neutrophil chemotaxis, degranulation, and respiratory burst. In the context of senescence, CXCR2 signaling reinforces the senescence program through a positive feedback loop.
Species-Specific and Evolutionary Aspects
In simple terms: Fish also have an IL-8 receptor that works similarly, showing this function is ancient.
The IL-8 receptor CXCR2 has been pharmacologically characterized in largemouth bass (Micropterus salmoides), demonstrating that the binding function is conserved across vertebrates. This conservation underscores the fundamental importance of GO:0005153 in immune defense.
Key Genes Involved in GO:0005153 interleukin-8 receptor binding
The following genes encode the ligands and receptors that mediate interleukin-8 receptor binding (GO:0005153) and its downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CXCL8 | Primary ligand (IL-8) that binds CXCR1/CXCR2 | Central to neutrophil recruitment and inflammation |
| CXCR1 | High-affinity receptor for IL-8 | Mediates IL-8 signaling in neutrophils |
| CXCR2 | Receptor for IL-8 and other ELR+ chemokines | Reinforces senescence and promotes tumorigenesis |
| CXCL1 | ELR+ chemokine that binds CXCR2 | Shares receptor with IL-8, modulates inflammation |
| CXCL2 | ELR+ chemokine that binds CXCR2 | Involved in neutrophil recruitment |
| CXCL3 | ELR+ chemokine that binds CXCR2 | Angiogenic and inflammatory roles |
| CXCL5 | ELR+ chemokine that binds CXCR2 | Promotes angiogenesis and cancer progression |
| CXCL6 | ELR+ chemokine that binds CXCR1/CXCR2 | Involved in inflammation and tumor growth |
| CXCL7 | ELR+ chemokine that binds CXCR2 | Platelet-derived, roles in wound healing |
| GNAI1 | G-protein alpha subunit downstream of CXCR1/2 | Mediates chemokine signaling |
| GNAI2 | G-protein alpha subunit downstream of CXCR1/2 | Mediates chemokine signaling |
| ARRB1 | Beta-arrestin, regulates receptor desensitization | Controls CXCR1/2 internalization |
| ARRB2 | Beta-arrestin, regulates receptor desensitization | Controls CXCR1/2 internalization |
| PIK3CA | PI3K catalytic subunit downstream of CXCR1/2 | Drives AKT signaling and chemotaxis |
| MAPK1 | ERK2, downstream of CXCR1/2 | Regulates gene expression and proliferation |
| MAPK3 | ERK1, downstream of CXCR1/2 | Regulates gene expression and proliferation |
| NFKB1 | Transcription factor activated by IL-8 signaling | Induces inflammatory gene expression |
How Is interleukin-8 receptor binding Regulated?
Interleukin-8 receptor binding is regulated at multiple levels. Ligand availability is controlled by secretion, glycosaminoglycan sequestration, and proteolytic processing. Receptor levels are modulated by transcriptional regulation and receptor internalization via beta-arrestins. The monomer-dimer equilibrium of IL-8 itself acts as a switch: dimer dissociation is required for CXCR1 binding, and disulfide-trapped dimers show altered activity. Additionally, heparin and alpha2-macroglobulin can inhibit IL-8 binding, providing extracellular control. These regulatory layers ensure that IL-8 signaling is tightly spatiotemporally controlled.
interleukin-8 receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CXCL8 | Psoriasis, inflammation | CXCL8 knockout mouse or human keratinocyte KO |
| CXCR2 | Senescence, cancer | CXCR2 knockout mouse or cancer cell line KO |
| CXCR1 | Neutrophil dysfunction | CXCR1 knockout neutrophil-like HL-60 cells |
| CXCL1 | Rheumatoid arthritis | CXCL1 transgenic mouse |
| CXCL5 | Tumor angiogenesis | CXCL5 overexpression in cancer cells |
Inflammation and Skin Diseases
IL-8 receptor binding is a key driver of neutrophil infiltration in inflammatory skin diseases such as psoriasis and dermatitis. Elevated IL-8 levels and increased CXCR1/CXCR2 expression on keratinocytes and neutrophils perpetuate inflammation. Targeting this interaction with antagonists is a therapeutic strategy for inflammatory skin disorders.
Cancer and Senescence
CXCR2 signaling via IL-8 receptor binding reinforces cellular senescence, a tumor-suppressive mechanism, but in some contexts, it promotes tumor progression by enhancing angiogenesis and neutrophil recruitment. The dual role of IL-8 receptor binding in cancer underscores the need for context-specific targeting.
Infectious and Immune Disorders
Dysregulated IL-8 receptor binding impairs neutrophil recruitment, leading to increased susceptibility to infections. Conversely, excessive binding can cause tissue damage in sepsis and acute lung injury. Modulating this interaction is therefore a double-edged sword in infectious diseases.
From interleukin-8 receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CXCR2 mediate senescence reinforcement? | CXCR2 knockout in human fibroblasts |
| What is the affinity of IL-8 monomer for CXCR1 N-domain? | Point mutations in CXCR1 N-terminal domain |
| Does dimer dissociation regulate receptor binding? | Disulfide-trapped IL-8 dimer knock-in |
| How does heparin modulate IL-8 binding? | Heparin-binding site point mutants of CXCL8 |
| Is CXCR2 function conserved in fish? | CXCR2 knockout in largemouth bass cell lines |
| Can IL-8 receptor binding be blocked therapeutically? | Overexpression of dominant-negative CXCR2 |
How to Study the interleukin-8 receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Affinity and receptor density | Characterizing CXCR1/CXCR2 binding |
| Surface plasmon resonance | Kinetics (kon, koff) of binding | Screening IL-8 mutants |
| Isothermal titration calorimetry | Thermodynamics of binding | Dissecting enthalpy/entropy |
| Calcium flux assay | G-protein activation | Functional response to IL-8 |
| Chemotaxis assay | Cell migration | Neutrophil recruitment |
| NMR spectroscopy | Structural changes upon binding | IL-8 dimer-monomer equilibrium |
| CRISPR knockout screen | Genes affecting binding/signaling | Unbiased discovery of regulators |
Binding Assays
Radioligand binding assays and surface plasmon resonance (SPR) are used to measure the affinity and kinetics of IL-8 binding to CXCR1/CXCR2. Isothermal titration calorimetry provides thermodynamic parameters. These methods directly quantify GO:0005153 activity.
Cell-Based Signaling Assays
Calcium flux assays, chemotaxis assays, and reporter gene assays measure downstream signaling after IL-8 receptor binding. These functional readouts confirm that binding leads to biological responses.
Structural Biology
NMR and X-ray crystallography have been used to solve structures of IL-8 and its complexes with receptor N-terminal domains, revealing the binding interface. These structural insights guide drug design.
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes that modulate IL-8 receptor binding and signaling, uncovering novel regulators. Such screens are powerful for unbiased discovery.
How CRISPR Can Be Used to Study GO:0005153 interleukin-8 receptor binding
Knockout
CRISPR knockout of CXCR1 or CXCR2 in neutrophil-like cell lines (e.g., HL-60) abolishes IL-8 receptor binding and downstream signaling, providing a clean background to study the function of GO:0005153. Knockout of CXCL8 in cancer cells reduces autocrine signaling and tumor growth.
Point Mutation
Point mutations in the N-terminal domain of CXCR1 (e.g., acidic residues) can be introduced to map the binding interface and quantify affinity changes. Similarly, mutations in the IL-8 dimer interface can stabilize the monomer or dimer to test their binding properties.
Knock-in
Knock-in of tagged CXCR2 (e.g., GFP or HA) allows live-cell imaging of receptor trafficking and binding in real time. Knock-in of disease-associated variants can model altered IL-8 binding in human diseases.
Overexpression
Overexpression of CXCR1 or CXCR2 in heterologous cells (e.g., HEK293) enhances IL-8 binding capacity and signaling, enabling biochemical studies. Overexpression of IL-8 itself can drive autocrine proliferation in cancer models.
How EDITGENE Supports interleukin-8 receptor binding Research
Researchers studying interleukin-8 receptor binding-related genes often need to determine whether a candidate gene is causally involved in ligand-receptor interactions, signaling, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this discovery, from knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for interleukin-8 receptor binding research.
Frequently Asked Questions About interleukin-8 receptor binding
What is interleukin-8 receptor binding?
Interleukin-8 receptor binding (GO:0005153) is the molecular function of binding to an interleukin-8 receptor, typically CXCR1 or CXCR2, initiating chemokine signaling.
What genes are involved in interleukin-8 receptor binding?
Key genes include CXCL8 (IL-8), CXCR1, CXCR2, and related ELR+ chemokines such as CXCL1, CXCL2, and CXCL5.
What is the GO ID for interleukin-8 receptor binding?
The GO ID is GO:0005153.
How does IL-8 bind to its receptor?
IL-8 binds the N-terminal domain of CXCR1/CXCR2, with monomer-dimer equilibrium and glycosaminoglycans modulating the interaction.
What diseases are associated with IL-8 receptor binding?
It is linked to inflammatory skin diseases, cancer, senescence, and infectious diseases.
Can CRISPR be used to study interleukin-8 receptor binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect this function.
What is the role of CXCR2 in senescence?
CXCR2 signaling via IL-8 receptor binding reinforces senescence, acting as a tumor-suppressive mechanism.
How is IL-8 receptor binding regulated?
It is regulated by ligand dimerization, heparin, alpha2-macroglobulin, and receptor internalization.
What methods measure IL-8 receptor binding?
Radioligand binding, surface plasmon resonance, isothermal titration calorimetry, and calcium flux assays are commonly used.
Why is interleukin-8 receptor binding important for drug discovery?
Blocking this interaction can attenuate pathological inflammation and cancer progression, making it a therapeutic target.
Conclusion
GO:0005153 (interleukin-8 receptor binding) is a fundamental molecular function that governs neutrophil recruitment, inflammation, and cancer biology. The interaction between IL-8 and CXCR1/CXCR2 is finely tuned by ligand oligomerization, glycosaminoglycans, and receptor N-terminal domain engagement. Dysregulation of this binding contributes to diseases ranging from psoriasis to tumor progression. CRISPR-based models, including knockout, point mutation, knock-in, and overexpression, are powerful tools to dissect the causal roles of genes involved in this function. EDITGENE offers comprehensive services to support such research, from custom cell line generation to library screening and bioinformatics.
References
- 1. Matsushima K et al.. 2022. Interleukin-8: An evolving chemokine.. Cytokine 153:155828 PMID: 35247648
- 2. Rajarathnam K et al.. 2006. Probing receptor binding activity of interleukin-8 dimer using a disulfide trap.. Biochemistry 45(25):7882-8 PMID: 16784240
- 3. Acosta JC et al.. 2008. Chemokine signaling via the CXCR2 receptor reinforces senescence.. Cell 133(6):1006-18 PMID: 18555777
- 4. Fernando H et al.. 2007. Thermodynamic characterization of interleukin-8 monomer binding to CXCR1 receptor N-terminal domain.. FEBS J 274(1):241-51 PMID: 17222184
- 5. Kemény L et al.. 1994. Role of interleukin-8 receptor in skin.. Int Arch Allergy Immunol 104(4):317-22 PMID: 8038609
- 6. Ramdin L et al.. 1998. Regulation of interleukin-8 binding and function by heparin and alpha2-macroglobulin.. Clin Exp Allergy 28(5):616-24 PMID: 9645599
- 7. Zhao Z et al.. 2022. Pharmacological characterization and biological function of the interleukin-8 receptor, CXCR2, in largemouth bass (Micropterus salmoides).. Fish Shellfish Immunol 120:441-450 PMID: 34933090
- 8. Fernando H et al.. 2004. Dimer dissociation is essential for interleukin-8 (IL-8) binding to CXCR1 receptor.. J Biol Chem 279(35):36175-8 PMID: 15252057
